Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)

Lignende værker

• Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
  af: Klipping, Christine, et al.
  Udgivet: (2012)
• Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
  af: Klipping, Christine, et al.
  Udgivet: (2012)
• Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
  af: Momoeda, Mikio, et al.
  Udgivet: (2020)
• Ethinylestradiol(30μg)-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
  af: Ilie, Ioana Rada, et al.
  Udgivet: (2012)
• Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
  af: Wiegratz, Inka, et al.
  Udgivet: (2015)